Last reviewed · How we verify
Venetoclax Oral Product
Venetoclax Oral Product is a Small molecule drug developed by The Lymphoma Academic Research Organisation. It is currently in Phase 2 development. Also known as: Venclyxto.
At a glance
| Generic name | Venetoclax Oral Product |
|---|---|
| Also known as | Venclyxto |
| Sponsor | The Lymphoma Academic Research Organisation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML (NA)
- Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS (PHASE1, PHASE2)
- Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (PHASE1, PHASE2)
- Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (PHASE1)
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) (PHASE2, PHASE3)
- Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Venetoclax Oral Product CI brief — competitive landscape report
- Venetoclax Oral Product updates RSS · CI watch RSS
- The Lymphoma Academic Research Organisation portfolio CI
Frequently asked questions about Venetoclax Oral Product
What is Venetoclax Oral Product?
Venetoclax Oral Product is a Small molecule drug developed by The Lymphoma Academic Research Organisation.
Who makes Venetoclax Oral Product?
Venetoclax Oral Product is developed by The Lymphoma Academic Research Organisation (see full The Lymphoma Academic Research Organisation pipeline at /company/the-lymphoma-academic-research-organisation).
Is Venetoclax Oral Product also known as anything else?
Venetoclax Oral Product is also known as Venclyxto.
What development phase is Venetoclax Oral Product in?
Venetoclax Oral Product is in Phase 2.
Related
- Manufacturer: The Lymphoma Academic Research Organisation — full pipeline
- Also known as: Venclyxto
- Compare: Venetoclax Oral Product vs similar drugs
- Pricing: Venetoclax Oral Product cost, discount & access